Hormone therapy linked to brain shrinkage, but not lesions

January 12, 2009

Two new studies show that commonly prescribed forms of postmenopausal hormone therapy may slightly accelerate the loss of brain tissue in women 65 and older beyond what normally occurs with aging.

The studies' findings appear as companion papers in the Jan. 13 issue of Neurology, the medical journal of the American Academy of Neurology. Both papers report on analyses from the Women's Health Initiative Memory Study, a substudy of the National Institutes of Health's (NIH's) landmark Women's Health Initiative (WHI) hormone therapy clinical trials.

Previous studies showed that hormone therapy in the form of conjugated equine estrogens (CEEs), with or without added progestin, increased the likelihood that older women would have difficulty with thinking skills and memory and experience dementia or cognitive impairment. Because these drugs are known to increase women's risk for strokes, it had been assumed that these drugs adversely affected women's memory by increasing the rates of "silent strokes" and brain lesions, changes in tissue that occur when blood flow to an area of the brain is reduced or blocked.

Instead, investigators found that the volumes of brain lesions were not significantly increased among women prescribed hormone therapy, but that the total volumes of brain tissue in regions critical to memory were slightly smaller.

CEEs, which are components of PremarinTM and PremProTM, have been used extensively for treating menopausal symptoms.

In the first of the two studies, a research team led by Laura H. Coker, Ph.D., of Wake Forest University Baptist Medical Center, did not find support for the hypothesis that hormone therapy was linked to increases in small vascular lesions in the brain or silent strokes.

"We asked," Coker said, "what is the most likely mechanism of the negative effect of hormone therapy on thinking and memory? We thought it was silent cerebrovascular disease. So we designed a study to obtain MRI scans of women's brains to look for increased volumes of brain lesions among those participants who had taken hormone therapy, compared to those who had not." More than 1,400 women, ages 71 to 89, who had previously participated in the WHI hormone therapy studies for an average of four to six years, participated. "This is not what we expected to find," Coker said.

In the companion paper, researchers report that the women who had taken hormone therapy had slightly smaller brain volumes in two critical areas of the brain: the frontal lobe and the hippocampus. Both areas are involved in thinking and memory skills, and loss of volume in the hippocampus is a risk factor for dementia.

"Our findings suggest one possible explanation for the increased risk for dementia in older women who had previously taken post-menopausal hormone therapy in the Women's Health Initiative Memory Study," said Susan Resnick, Ph.D., of the National Institute on Aging, which is part of NIH. Resnick was the lead author for the second paper. "Our findings suggest that hormone therapy in older post-menopausal women has a negative effect on brain structures important in maintaining normal memory functioning. However, this negative effect was most pronounced in women who already may have had some memory problems before using hormone therapy, suggesting that the therapy may have accelerated a neurodegenerative disease process that had already begun."

Current recommendations are that hormone therapy be used only if needed to treat menopausal symptoms, and taken at the lowest dose and for the shortest time possible to relieve symptoms, which generally appear in women age 48 to 55. Women age 65 and older should not begin hormone therapy because the risks outweigh possible benefits. The new information suggests that older women who were already having some cognitive problems at the time they began hormone therapy are most at risk for negative effects on the brain. However, the findings also suggest that women who were healthy at the time they began hormone therapy were less likely to have any adverse effects on the brain, Resnick said.

Researchers will next set out to determine whether the negative effects of hormone therapy on brain volumes continue over time through follow-up MRI studies of the women studied. In addition, it will be important to examine younger women who took hormone therapy closer to the timing of menopause to determine whether they show a different pattern of effects on cognitive function and brain structure, Coker said.

Source: Wake Forest University

Explore further: Many women do not follow contraception guidelines after weight-loss surgery, study finds

Related Stories

Many women do not follow contraception guidelines after weight-loss surgery, study finds

October 18, 2017
Many women do not follow the guidelines to prevent pregnancy for an 18-month period following bariatric surgery, University of Pittsburgh researchers examining post-surgery contraceptive practices and conception rates report.

Therapeutic form of arsenic is a potential treatment for deadly type of brain cancer

October 17, 2017
From Sherlock Holmes to Agatha Christie, arsenic is often the poison of choice in popular whodunits. But in ultra-low dosage, and in the right form, this naturally occurring chemical element can be a potent force against ...

Too little fat is bad for cardiovascular health and leptin therapy may help

October 16, 2017
We know that too much body fat is generally bad for our cardiovascular system, and now scientists are learning more about how too little fat yields some of the same damage.

Endogenous infection marker guides antibiotic therapy

October 16, 2017
The endogenous infection marker procalcitonin can help to guide the use of antibiotics when treating infections. The course of antibiotic therapy is shortened, and its side effects and mortality rate also decrease, as researchers ...

Breast cancer screenings still best for early detection

October 12, 2017
(HealthDay)—Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.

Biology of childhood brain tumor subtypes offers clues to precision treatments

October 17, 2017
Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood ...

Recommended for you

Inflammation trains the skin to heal faster

October 18, 2017
Scars may fade, but the skin remembers. New research from The Rockefeller University reveals that wounds or other harmful, inflammation-provoking experiences impart long-lasting memories to stem cells residing in the skin, ...

Large variety of microbial communities found to live along female reproductive tract

October 18, 2017
(Medical Xpress)—A large team of researchers from China (and one each from Norway and Denmark) has found that the female reproductive tract is host to a far richer microbial community than has been thought. In their paper ...

Study of what makes cells resistant to radiation could improve cancer treatments

October 18, 2017
A Johns Hopkins University biologist is part of a research team that has demonstrated a way to size up a cell's resistance to radiation, a step that could eventually help improve cancer treatments.

New approach helps rodents with spinal cord injury breathe on their own

October 17, 2017
One of the most severe consequences of spinal cord injury in the neck is losing the ability to control the diaphragm and breathe on one's own. Now, investigators show for the first time in laboratory models that two different ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

New method to measure how drugs interact

October 17, 2017
Cancer, HIV and tuberculosis are among the many serious diseases that are frequently treated with combinations of three or more drugs, over months or even years. Developing the most effective therapies for such diseases requires ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

morpheus2012
1 / 5 (2) Jan 12, 2009
yeah another sponsored news

from the coporate pharma elite

dont take hormones couse its slashes there profits

by about 30 procent for evry indivioual who use hrt

obey sheep

to the world elite

just lke the poster of this gay comercial

this article has something comon with sciense like

a frog from from amazon has with a mars bacteria

hey if u trace it back few biiillion years

u might find a single nucleotiede matching

wake up before its to late

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.